ProKidney prepares to go public through a USD 2.6 billion SPAC merger
Category: #headlines  | By Mateen Dalal  | Date: 2022-01-20 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

ProKidney prepares to go public through a USD 2.6 billion SPAC merger

 

  • The IPO is expected to offer gross cash proceeds of around USD 825 million.
  • ProKidney’s lead product “REACT” is known to stabilize, slow, and even reverse kidney failure.

ProKidney, a therapeutic venture focused on treating chronic kidney disease, is reportedly planning to go public by entering a definitive merger agreement with Social Capital Suvretta Holdings, a special purpose acquisition company (SPAC).

The deal will value ProKidney at USD 2.64 billion and is likely to be finalized by the third quarter of this year. According to reliable sources, the IPO is expected to offer gross cash proceeds of around USD 825 million.

For those unaware, ProKidney specializes in offering disease-altering autologous cell therapy for treating CKD (chronic kidney disease). The firm’s lead product, coined as “REACT” is known to stabilize, slow, and even reverse kidney failure.

REACT operates based on cell therapy that is derived from a patient’s kidney cells. The procedure is known to be minimally invasive and potentially reverses CKD development.

Even Social Capital’s founder Chamath Palihapitiya expressed enthusiasm about the firm’s potential to develop a treatment for CKD that could potentially be less invasive than traditional dialysis.

Early results from REACT’s clinical trial showed that it can regenerate kidney function, which in turn could allow ProKidney to revolutionize CKD treatment. Palihapitiya added that this could be a game-changer for one of the most expensive and prevalent diseases.

According to ProKidney CEO Tim Bertram, chronic kidney disease is one of the most burdensome chronic conditions to treat, affecting over 75 million patients in the U.S. and the EU alone. The company intends to transform CKD treatment using its technological breakthroughs in cellular therapies.

If market speculations are right, the global CKD treatment market was valued at USD 81 billion in 2019 and is likely to account for over USD 133 billion by the year 2027.

Source Credits –

https://capital.com/prokidney-set-to-go-public-via-spac-headed-by-embroiled-ceo

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

TagZ Foods aims for $128 million sales to expand product portfolio

TagZ Foods aims for $128 million sales to expand product portfolio

By Mateen Dalal

TagZ Foods, a leading snacks brand, has reportedly claimed the possibility to be the nation’s fastest direct-to-consumer food company to reach the annual sales mark of USD 128 million approx. The brand aims to increase its manufacturing units t...

MediaTek unveils first mmWave Chipset to support 5G smartphones

MediaTek unveils first mmWave Chipset to support 5G smartphones

By Mateen Dalal

MediaTek has announced the launch of Dimensity 1050 system-on-chip, the first mmWave 5G chipset that will support the advanced generation of 5G equipped smartphones with seamless connectivity and display, power efficiency, and gaming. As per repor...

Pintarnya to develop a super app for blue collar workers in Indonesia

Pintarnya to develop a super app for blue collar workers in Indonesia

By Mateen Dalal

Pintarnya, a job upskilling platform based out of Indonesia, has reportedly announced that it plans to develop a new app for the 60 million blue-collar workers of Indonesia who often face uncertainty and scams while looking for a job. As per repor...